Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones
Feb 16, 2017 12:01 pm UTC| Business
- Ivosidenib (AG-120) NDA Submission for IDH1m R/R AML Planned by Year End 2017; First Phase 1 Expansion Data Expected in the Second Half of 2017 - - AG-348 Pivotal Trial Design Update Expected in the Third Quarter of...
Feb 16, 2017 12:01 pm UTC| Business
BASEL, Switzerland and WATERTOWN, Mass., Feb. 16, 2017 -- Lonza Houston, Inc., a global leader in viral gene and cell therapy manufacturing, and Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage...
Feb 16, 2017 12:01 pm UTC| Business
BASEL, Switzerland and WATERTOWN, Mass., Feb. 16, 2017 -- Lonza Houston, Inc., a global leader in viral gene and cell therapy manufacturing, and Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage...
Feb 16, 2017 12:01 pm UTC| Business
TEL-AVIV, Israel, Feb. 16, 2017 -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late...
Feb 16, 2017 12:01 pm UTC| Business
TEL-AVIV, Israel, Feb. 16, 2017 -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late...
XOMA Appoints Matthew Perry to its Board of Directors
Feb 16, 2017 12:01 pm UTC| Business
BERKELEY, Calif., Feb. 16, 2017 -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Matthew Perry, President of BVF Partners L.P....
XOMA Appoints Matthew Perry to its Board of Directors
Feb 16, 2017 12:01 pm UTC| Business
BERKELEY, Calif., Feb. 16, 2017 -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Matthew Perry, President of BVF Partners L.P....